Quam Securities

Since its inception in 1986, Quam Securities Limited (Quam Securities) has grown to become one of the few mid-tier securities brokerages in Hong Kong with global execution capabilities for both private and institutional clients. It boasts a well-established network in Greater China including Taiwan and in major world markets through the Global Alliance Partners (GAP). Quam Securities is well-positioned not only to harness and drive business within the China Tonghai International Financial Limited but also between China and the world markets.

Research from Quam Securities

Research from Quam Securities, Quam Securities

Quam Securities Research

Equity Bottom-Up

<ul>
<li>InnoCare (9969 HK, NR) announces that InnoCare has entered into a strategic research collaboration and license agreement with Eli Lilly (LLY US, NR) to develop new medicines.</li>
<li>InnoCare will be eligible to receive up to US$100mn in upfront and near-term payments and up to approximately US$3.25bn in development and commercial milestone payments, in each case subject to applicable conditions and the achievement of relevant milestones.</li>
<li>This collaboration shows InnoCare’s R&amp;D capabilities.</li>
</ul>


InnoCare (9969 HK, NR) announces that InnoCare has entered into a strategic research collaboration and license agreement with Eli Lilly (LLY US, NR) to develop new medicines.
InnoCare will be eligible to receive up to US$100mn in upfront and near-term payments and up to approximately US$3.25bn in development and commercial milestone payments, in each case subject to applicable conditions and the achievement of relevant milestones.
This collaboration shows InnoCare’s R&amp;D capabilities.


Zhongfu Straits Pingtan Develpmnt (000592 CH)

InnoCare Pharma

Quam Morning Note (25 Sep) - InnoCare